Skip to main content Skip to search

Respiratory Diseases

Description

The research group on Respiratory Diseases focuses on the study of the determinants of health conditions in patients with respiratory diseases and the clinical implications of these findings, the evaluation and updating of the protocols for action, the identification of biomarkers (diagnostics, prognoses and therapeutics), of new therapeutic options, the improvement of the quality and the optimization in the assistance.

The general objectives of the research group are:

  1. NEOPLASIAS TORÁCCICAS LUNG CANCER AND PLEURA line: Identify a set of clinical-molecular variables that improve the prognostic and predictive capacity of TNM and clinical translation of these results.
  2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE line: To study the clinical, biological, microbiological, radiological, functional determinants of progression and severity. Evaluate new endoscopic treatment in obstructive airway disease and the impact of different approaches to health care in the management of disease activity.
  3. ASTHMA line: Study the clinical, biological, microbiological, radiological, functional, progression and severity determinants. To evaluate new endoscopic treatments in obstructive airway pathology and the impact of different approaches to health care in the management of disease activity.
  4. PULMONARY HYPERTENSION (HP) line: Establish a network of groups with complementary capabilities of research aimed at identifying new markers for assessing disease activity and new therapeutic targets for the treatment of pulmonary hypertension following a strategy of translational research, with the ultimate aim of contributing to alleviate and cure the disease.
  5. INSTERSTICIALES DISEASES AND FIBROSIS line: Create a record of well-characterized patients, and incorporate new treatments in their care, measuring the impact on quality of life, progression and prevention of exacerbations.
  6. SAHS & NO INVASIVE VENTILATION (NIV) line: Develop new ways of simplified diagnosis, deepen treatment indications and establish new indications for NIV outside the critical care units. Investigate the causes of failure of NIV and asynchrony.
  7. RESEARCH IN LUNG TRANSPLANTATION line: Advance knowledge of the causes of rejection and infection and diagnosis, and expand the selection criteria organ donor and recipient.
  8. INTERVENTIONS IN EPIDEMIOLOGY AND PUBLIC HEALTH line: Identify new target groups and new opportunities for intervention on smoking.
  9. PNEUMONIA line: Assess the effectiveness in the prognostic estimation of new biological markers of community pneumonia.